Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Tempus AI secures $1.1 billion in data contracts, shares rally
Tempus AI said it signed $1.1 billion in sealed data contracts with 70 customers in 2025, including major life-sciences firms such as AstraZeneca, Pfizer, Merck and Abbvie. The company reported revenue retention around 126% and called 2025 a record year for its Data and Applications business. Shares rose as much as 15% intraday and closed up 4.51% at $69.26. Tempus AI plans to finalize and report full 2025 financial results on an earnings call in February 2026. » More on finance.yahoo.com
Tempus AI raises FY25 guidance, cites FDA clearance and Paige acquisition as growth drivers
Tempus AI guided FY25 revenue to $1.25–$1.26 billion (about 81% YoY) and expects roughly $1.55 billion in FY26 revenue, valuing the company at ~9.16x 2026 sales. Recent catalysts include FDA clearance for its xR IVD product and the $81 million acquisition of Paige, which expand addressable markets and AI pathology capabilities. Analysts note strong revenue visibility and execution, while valuation appears supported by forward growth despite a trailing P/E around 41.5 and elevated share performance since April. » More on finance.yahoo.com
Tempus AI reaches all-time high of $98.14
Tempus AI stock climbed to an all-time high of $98.14, bringing market capitalization to about $16.16 billion. Analyst price targets range from $60 to $100; Guggenheim raised its target to $95 and H.C. Wainwright to $98. Tempus recorded revenue growth of 59.84% over the last twelve months and a 1-year performance of +96.54%. The company received FDA 510(k) clearance for the RNA-based diagnostic Tempus xR IVD and expanded its CARE program for breast cancer screening. » More on de.investing.com
ARK Invest increases stake in AMD and divests heavily from Tempus AI
Cathie Wood’s ARK ETFs bought 25,899 shares of Advanced Micro Devices through ARKF on September 16, worth about $4.17 million. At the same time, a total of 167,598 shares of Tempus AI were sold via ARKK and ARKG for roughly $14.27 million, part of an ongoing reallocation toward selected technology and biotech names. » More on de.investing.com
Cathie Woods' ARK ETFs sell Tempus AI and buy Arcturus
In the trading session on September 15, 2025, Cathie Woods' ARK ETFs adjusted their portfolios: via ARKG, 7,270 shares of Tempus AI were sold for $627,982, while 27,408 shares of Arcturus were purchased for $474,706. At the same time, ARK made buys in Bullish, eToro, Figma and Toast and sales of Kratos, Rocket Lab and Shopify. The transactions point to a strategic reshuffle within the fund's biotechnology and AI positions. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 73.2k | 2.72% |
| Gross profit | 36.96k | 2.92% |
| Net profit | -34.56k | 11.85% |
| EBITDA | 2.21k | 243.99% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.81m |
Number of shares | 30.48m |
52-week high/low | €0.0954 - €0.0254 |
| Dividends | No |
Beta | -0.04 |
P/E ratio | -17.26 |
PEG ratio | 8.68 |
P/B ratio | 2.62 |
P/S ratio | 8.96 |
Company profile
Tempus Capital Inc. operates as a real estate operating company in Canada. The company's real estate portfolio includes four properties comprising a commercial plaza, one commercial property, and two mixed commercial/residential properties in Ontario. Tempus Capital Inc. was incorporated in 2011 and is based in Burlington, Canada.
| Name | TEMPUS CAPITAL INC. |
| CEO | Russell Tanz |
| Headquarters | Burlington,
on Canada |
| Website | |
| Industry | Machinery |
| IPO | 28/02/2019 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Cnq | TEMP.CN |